X
[{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Provides Company Update on Phase II Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Receives FDA IND Authorization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Clinical Study (\"Study II\") Progress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase\u00ae Provides Update on Phase II Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Phase Ib NMIBC Clinical Study Published","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase\u00ae Closes $2.5M Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase\u00ae Commences $CAN 2.5 M Follow-On Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase \u00ae Closes Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase\u00ae Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Technologies Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Closes Non-Brokered Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase(R) Provides Update on Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Announces Brokered LIFE Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Theralase Technologies
Filters
Companies By Therapeutic Area
Details:
The net proceeds will be used for the development of Ruvidar (TLD-1433), a novel photosensitizer, currently being evaluated in a phase II clinical trial for treating high-risk non-muscle invasive bladder cancer.
Lead Product(s):
TLD-1433
Therapeutic Area: Oncology
Product Name: Ruvidar
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
TSX Venture Exchange
Deal Size: $0.8 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
February 05, 2024
Details:
TLD-1433 (ruvidar) is a ruthenium-based photodynamic compound. It is under phase 2 clinical development for the treatment of patients with non-muscle invasive bladder cancer.
Lead Product(s):
TLD-1433
Therapeutic Area: Oncology
Product Name: Ruvidar
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 15, 2024
Details:
The Company plans to use the proceeds to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study evaluating Ruvidar (TLD-1433), a light-activated compound.
Lead Product(s):
TLD-1433 ,Photodynamic Therapy
Therapeutic Area: Oncology
Product Name: Ruvidar
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Research Capital Corporation
Deal Size: $0.8 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
November 29, 2023
Details:
The Company plans to use the proceeds to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study evaluating Ruvidar (TLD-1433), a light-activated compound.
Lead Product(s):
TLD-1433 ,Photodynamic Therapy
Therapeutic Area: Oncology
Product Name: Ruvidar
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Research Capital Corporation
Deal Size: $1.1 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
November 17, 2023
Details:
The Company plans to use the proceeds to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study evaluating Ruvidar (TLD-1433), a light-activated compound.
Lead Product(s):
TLD-1433
Therapeutic Area: Oncology
Product Name: Ruvidar
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Research Capital Corporation
Deal Size: $2.6 million
Upfront Cash: Undisclosed
Deal Type: Financing
October 23, 2023
Details:
TLD-1433 on activation by radiation therapy has been demonstrated to be effective in the destruction of human GBM cancer cells. Currently being investigated for non-muscle invasive bladder cancer.
Lead Product(s):
TLD-1433
Therapeutic Area: Oncology
Product Name: TLD-1433
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 23, 2023
Details:
Ruvidar (TLD-1433), is an exciting new drug candidate for the treatment for NMIBC and has been proven to be safe and effective in a phase Ib clinical study in the safe and effective treatment of NMIBC.
Lead Product(s):
TLD-1433 ,Photodynamic Therapy
Therapeutic Area: Oncology
Product Name: Ruvidar
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 16, 2023
Details:
The Company intends to use the proceeds for the advancement of Phase II non-muscle invasive bladder cancer clinical study evaluating TLD 1433, a ruthenium metal-based molecule.
Lead Product(s):
TLD-1433
Therapeutic Area: Oncology
Product Name: Ruvidar
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $0.9 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
June 30, 2023
Details:
TLD-1433 on activation by radiation therapy has been demonstrated to be effective in the destruction of human GBM cancer cells. Currently being investigated for non-muscle invasive bladder cancer.
Lead Product(s):
TLD-1433
Therapeutic Area: Oncology
Product Name: TLD-1433
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 02, 2023
Details:
TLD-1433 is a patented PDC with 12 years of published peer reviewed preclinical research and is currently under investigation in Study II. Study II utilizes the therapeutic dose of TLD-1433 (0.70 mg/cm2) activated by the proprietary TLC-3200 medical laser system.
Lead Product(s):
TLD-1433
Therapeutic Area: Oncology
Product Name: TLD-1433
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 25, 2023